Selected article for: "body surface and necrosis factor"
Author: Jone, Pei-Ni; Everitt, Melanie D.
Title: Management of Multisystem Inflammatory Syndrome in Children Associated with COVID-19 Infection
  • Cord-id: 5ahh4g13
  • Document date: 2021_5_6
    • ID: 5ahh4g13
    Snippet: PURPOSE OF REVIEW: The purpose of this review is to summarize what is known about multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection. RECENT FINDINGS: The timing of presentation and features of diagnosis are described. Cardiac involvement is common and is the focus of this review. Arrhythmias, heart block, acute heart failure, shock, cardiac dysfunction, and coronary dilation have all been reported. Therapies used to treat children with this hyperinflammatio
    Document: PURPOSE OF REVIEW: The purpose of this review is to summarize what is known about multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection. RECENT FINDINGS: The timing of presentation and features of diagnosis are described. Cardiac involvement is common and is the focus of this review. Arrhythmias, heart block, acute heart failure, shock, cardiac dysfunction, and coronary dilation have all been reported. Therapies used to treat children with this hyperinflammation syndrome include supportive care and agents that modulate the immune system. Therapies commonly described include intravenous immunoglobulin, steroids, and cytokine-directed agents, particularly tumor necrosis factor-alpha blockade and interleukin receptor blockade. The threshold for diagnosing coronary involvement in MIS-C is coronary artery dimensions indexed to body surface that exceed the normative values (Z score >2). Those hospitalized with MIS-C are evaluated by electrocardiogram and echocardiogram; outpatient assessment by a cardiologist is indicated prior to sports clearance. SUMMARY: The prognosis of treated MIS-C patients is good. Future work is needed to understand the scope of cardiac involvement associated with acute COVID-19 and MIS-C in children and to define the optimal therapeutic targets for these distinct entities.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adjunctive treatment: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
    • acute ards respiratory distress syndrome and lung macrophage: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and lung macrophage activation: 1
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and macrophage activation syndrome resemble: 1
    • acute coronary syndrome and adjunctive therapy: 1
    • acute coronary syndrome and adjunctive treatment: 1
    • acute coronary syndrome and long term outcome: 1, 2, 3
    • acute coronary syndrome and lv function: 1
    • acute coronary syndrome and lv left ventricle: 1
    • acute coronary syndrome and lymphocyte count: 1, 2
    • acute heart failure and adjunctive therapy: 1, 2
    • acute heart failure and long term outcome: 1, 2, 3
    • acute heart failure and lung alveolar: 1
    • acute heart failure and lymphocyte count: 1, 2, 3, 4, 5, 6